Skip to main content

Table 2 JRQLQ scores at baseline and second year of treatment (n = 9)

From: Effectiveness and safety of allergen immunotherapy in patients with allergic rhinitis complicated by rheumatic autoimmune diseases: a case series study

 

Baseline

2nd year

p value

Nasal and eye symptoms

1.67 (1.5–2.0)

0.67 (0–1.17) *

0.0141

QOL related questionnaires

 Usual daily activities

1.0 (0.8–1.4)

0 (0–0.8)

0.0575

 Outdoor activities

1.0 (0.5–2.0)

0 (0–0.5) *

0.0350

 Social functioning

0.67 (0.33–1.0)

0 (0–0)

0.584

 Impaired sleeping

2.0 (1.0–2.0)

0 (0–1.0)

0.0655

 Physical problems

1.0 (1.0–2.0)

0 (0–1.0)

0.114

 Emotional functions

1.0 (0.5–1.5)

0 (0–0)

0.106

General state

4.0 (3.8–4.0)

2.0 (1.0–2.0) *

0.0498

  1. The data are presented as median with interquartile ranges
  2. Comparison of each JRQLQ score between baseline and second year were calculated using the Wilcoxon signed rank test. *p < 0.05
Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us